Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model

Table 1 Trial facilities by patients and treatment administrations

				Study Patients					Administrations July 2019
Site	Gender	Security	Total Inmates 2019 Census (n)^a	Depot (on Monthly Administrations) (n)^b	Depot (on Weekly Administrations) (n)^b	Depot Total (n)	Methadone (n)^c	SBL BPN (n)^c	Depot (n)^b	Methadone (n)^c	SBL BPN (n)^c
Inner Metro 1	Male	Min	610	4	4	8	33	5	11	1,023	155
Inner Metro 2	Male	Min/Med/Max	451	5	3	8	16	1	12	496	31
Outer Metro 1	Female	Min/Med/Max	212	4	0	4	21	3	4	651	93
Regional 1	Male	Max	398	0	6	6	32	5	20	992	155
Regional 2	Male	Min/Max	526	10	0	10	32	12	10	992	372
Regional Remand	Male	Min/Med	627	0	5	5	53	13	18	1,643	403
Regional 3	Male	Max	420	9	0	9	52	1	9	1,612	31
Totals			3244	32	18	50	239	40	84	7409	1240

^aNSW Inmate Census 2019 [25]
^bTrial data. The number of depot administrations is greater than the number of patients because there was also weekly and titration dosing
^cMedian of monthly OAT reports: August 2018 to July 2019 [27]

ISSN: 1472-6963